Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.
- Noxopharm, Acrux and TruScreen topped the board after fresh data, a licensing deal and funding support.
- Neuren, Fisher & Paykel Healthcare and Aroa Biosurgery paired growth updates with stronger balance sheets.
- Several smaller names raised cash to fund trials, manufacturing and commercial rollouts.
- Some gap-up moves held through the week, while others gave back early gains as traders took profit.
- Aged care and healthcare services stocks improved on better cash flow, refinancing and operating resets.
Noxopharm (ASX:NOX) led the sector with a 34.37% weekly gain after releasing lab data for its Sofra platform. The company said the technology lifted a key immune signal more than 200-fold in human tissue. Investors cared because the result suggests the drug platform may make cancer treatments work better, though the work is still early and not yet proven in patients. Acrux (ASX:ACR) jumped 33.33% after amending its Lenzetto deal for Australia, with milestone payments worth up to A$5.4 million. TruScreen Group (ASX:TRU) climbed 29.37% as sales rose 42%, a large Vietnam screening program advanced, and the company completed an oversubscribed placement.
Biotech names rose on trial and regulatory news
Actinogen Medical (ASX:ACW) was flat for the week, but its update still mattered. The company said European regulators broadly agreed with earlier US guidance for Xanamem in Alzheimer’s disease. In plain English, that means the company now has a clearer list of what studies it needs before it can ask to sell the drug. Neuren Pharmaceuticals (ASX:NEU) added 6.36% after higher DAYBUE royalties and progress in its Phase 3 Koala trial for NNZ-2591. A Phase 3 trial is a large late-stage study used to test whether a drug works well enough and safely enough for approval. Amplia Therapeutics (ASX:ATX) rose 3.85% after mature pancreatic cancer data and a A$27.5 million raising, even though it also stopped a separate study because the chemo mix was too toxic. Elsewhere, Imugene (ASX:IMU) fell 11.54% despite starting a new combination cohort for azer-cel. That slide suggests investors wanted stronger near-term proof from patients, not just trial expansion. Neurizon Therapeutics (ASX:NUZ) dropped 7.46% even after enlarging its ALS trial cohort, perhaps because bigger studies can take longer and cost more, even when the company says current funding is enough. AdAlta (ASX:1AD) gained 12.50% after hiring US regulatory advisers for its CAR-T program, but the stock gave back part of its initial jump by week’s end. In simple terms, buyers liked the news first, then some locked in profits.Cash, royalties and profit mattered
Fisher & Paykel Healthcare (ASX:FPH) was one of the week’s strongest large-cap moves, rising 12.73% after revenue grew 14%, net profit rose 24% and the dividend increased 22%. Investors often reward that mix because it shows both growth and cash being returned to shareholders. Neuren also impressed on cash, ending the period with A$296 million in cash and short-term investments while DAYBUE royalties climbed 15% to A$65 million. That gave the company room to keep funding drug development while it reviews capital management. Across New Zealand healthcare and aged care, the tone was also firmer. Ryman Healthcare (ASX:RYM) rose 7.14% after sharply narrowing its loss and delivering its first positive free cash flow in more than a decade. Free cash flow means cash left after running the business and spending on assets. Third Age Health (ASX:TAH) gained 14.07% on higher profit and acquisitions, while Promisia Healthcare (ASX:PHL) and Green Cross Health (ASX:GXH) also reported stronger earnings. Radius Care (ASX:RAD) fell 4.76% despite cheaper debt and more funding capacity, which may mean investors want to see the growth projects produce results first.Contracts and expansion drove medtech interest
4DMedical (ASX:4DX) rose 9.67% after signing a three-year deal with SimonMed Imaging to roll out its lung imaging tools across more than 170 US sites. Investors cared because this is real customer use, not just a test or pilot. Alcidion (ASX:ALC) slipped 2.27% even after securing a $35 million UK patient record contract. The stock opened lower again after resuming trade, which suggests early support faded. IMEXHS (ASX:IME) also eased 2.78% despite winning a Mexico tender worth US$384,000 in annual recurring revenue. That kind of reaction often means the announcement was good, but not large enough to change short-term profit expectations. Aroa Biosurgery (ASX:ARX) climbed 11.20% after beating its own FY26 targets with NZ$103.9 million in revenue and much stronger earnings. Pacific Edge (ASX:PEB) gained 7.14% after a draft US Medicare policy proposed renewed cover for key Cxbladder tests. Medicare cover matters because it affects whether doctors get paid to use the test. The stock held its reopening level rather than pushing higher, so investors seem to be waiting for the draft policy to become final.Fresh money kept flowing, but not every raise was welcomed
Several companies tapped investors this week. Tetratherix (ASX:TTX) raised A$17 million to expand manufacturing. TruScreen added NZ$1.82 million in an oversubscribed placement. Amplia brought in A$27.5 million, while Nexalis Therapeutics (ASX:NX1) locked in a new A$53 million debt facility and returned to trading. Nexalis still fell 8.00%. Debt can avoid issuing more shares, but it also creates future repayment pressure. Anteris Technologies (ASX:AVR) dropped 4.96% after launching a US$250 million at-the-market stock sale, which means new shares can be sold gradually into the market. Investors often worry that more shares will reduce the value of each existing share. Some of the sharpest moves showed two different patterns. In names such as Noxopharm, TruScreen, Emyria (ASX:EMD) and Zoono (ASX:ZNO), buying stayed firm after trading reopened, which points to continued conviction from buyers. Emyria rose 16.67% after the TGA widened the types of therapists who can work in psychedelic-assisted treatment, a change that could help the company fill more appointments later this year. By contrast, Imugene, Alcidion and IMEXHS lost ground after reopening, which means early gains evaporated as the week went on. That usually happens when traders bank profits quickly or when the news is useful but not enough to change near-term revenue or approval chances.Bottom Line?
The next stretch will turn on dated milestones already on the calendar, including Actinogen’s XanaMIA results due in November 2026, PolyNovo’s planned late-2026 PMA filing, Alcidion’s June 2027 UK go-live target, and Neurizon’s early Q3 2027 topline timeline.
Questions in the middle?
- Will Pacific Edge’s draft Medicare cover become final, and how quickly could that restore US test volumes?
- Can Neuren keep DAYBUE royalty growth going after the US powder launch, and will that change its capital management plans?
- Which of this week’s cash raisings will turn into clear sales growth or stronger trial results over the next 6 to 12 months?